Investigation of the clinical efficacy of mesenchymal stem cells in combination with monoclonal antibody therapy against feline panleukopenia.
Yi Wang, Rui Yan, Ling Mao, Huikang Wang, Cong Zhu, Difei Wang, Yi Ding, Dengru Wang
Abstract
Feline panleukopenia is an acute and highly contagious disease caused by feline panleukopenia virus (FPV). Conventional therapeutic approaches often yield suboptimal outcomes in managing leukopenia, which consequently contributes to its high mortality rate. Mesenchymal stem cells (MSCs) are a type of multipotent stem cell characterized by their multidirectional differentiation potential and immunomodulatory capabilities. Studies have shown that MSCs possess the potential to treat inflammatory and immune-mediated diseases, support and promote hematopoiesis, and facilitate tissue repair. Therefore, this study was to investigate the clinical efficacy of combining MSCs with feline panleukopenia monoclonal antibody to propose a potential treatment for FPV.